167 related articles for article (PubMed ID: 30514181)
1. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A; Nekvindová J; Filip S
Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
[TBL] [Abstract][Full Text] [Related]
2. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan.
Salvador-Martín S; García-González X; García MI; Blanco C; García-Alfonso P; Robles L; Grávalos C; Pachón V; Longo F; Martínez V; Sanjurjo-Sáez M; López-Fernández LA
Pharmacol Res; 2018 Oct; 136():133-139. PubMed ID: 30213564
[TBL] [Abstract][Full Text] [Related]
4. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Schulz C; Boeck S; Heinemann V; Stemmler HJ
Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
[TBL] [Abstract][Full Text] [Related]
6. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
Treenert A; Areepium N; Tanasanvimon S
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
[TBL] [Abstract][Full Text] [Related]
7. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
8. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study.
Barnett-Griness O; Rennert G; Lejbkowicz F; Pinchev M; Saliba W; Gronich N
Clin Pharmacol Ther; 2023 Mar; 113(3):704-711. PubMed ID: 36537755
[TBL] [Abstract][Full Text] [Related]
9. Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity.
García Gil S; Ramos Díaz R; Nazco Casariego GJ; Llanos Muñoz M; Viña Romero MM; Martín Calero B; Pérez Pérez JA; Gutiérrez Nicolás F
Med Clin (Barc); 2018 Dec; 151(11):425-430. PubMed ID: 29499902
[TBL] [Abstract][Full Text] [Related]
10. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M; van Doorn L; Kloet E; van Veggel A; Matic M; de Neijs MJ; Oomen-de Hoop E; van Meerten E; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2023 Nov; 62(11):1589-1597. PubMed ID: 37715926
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
17. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
[TBL] [Abstract][Full Text] [Related]
20. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
